News

People with secondary progressive multiple sclerosis (SPMS) who began treatment with Mayzent early and continued its use for years are less likely to experience disability progression than those starting the medication later in their disease course, five-year data from the EXPAND study suggest. Data from this same Phase 3…

With the development of a cell line that produces significant amounts of Immutep‘s treatment candidate, IMP761, the company is preparing to advance its antibody into clinical testing for autoimmune conditions, including multiple sclerosis (MS). Immutep also reports that is adapting its manufacturing operations to comply with…

The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted applications from Genentech to shorten the infusion time for Ocrevus, an approved treatment for multiple sclerosis. If approved, the time to administer Ocrevus will be shortened to a two-hour session, instead…

Sanofi will host an online science session to present results of a Phase 2b clinical trial testing the safety and efficacy of its investigational, oral BTK inhibitor SAR442168 in people with multiple sclerosis (MS). The virtual session, owing to the cancellation of the American Academy…

The lack of a “chaperone” protein — called HLA-DO — that helps to protect the body against threats by presenting specific molecules (antigens) to immune cells to drive a response, promoted the development of a self-reactive immune system and autoimmune disease, according to a study in mice. Particularly, the work showed…

Scientists have identified a link between systemic inflammation and fat (lipid) metabolism that may underlie the increased risk of cardiovascular disease in people with multiple sclerosis (MS). The study with that finding, “Lipoprotein profiling in early…

The MIST Phase 2 clinical trial, supporting the potential of hematopoietic (blood cell-producing) stem cell transplant (HSCT) to significantly slow disability progression in highly active relapsing-remitting multiple sclerosis (RRMS) patients, has received a Distinguished Clinical Research Achievement Award from the Clinical Research (CR) Forum. Five years after the transplant, most…

Scientists have built a map of the toxic immune cells that contribute to neurodegeneration in multiple sclerosis (MS). Their findings may open the door to the development of new medications that protect the brain from the effects brought on by these harmful immune cells. Results were reported in the study,…

After being rejected twice in the last four years, Fampyra (fampridine; marketed as Ampyra in the U.S.) is now being recommended by the Scottish Medicines Consortium (SMC) for use in the country’s National Health System (NHS) to treat walking disabilities in adults with multiple sclerosis (MS). Scotland…

People in Japan with lesions in the cerebral cortex due to multiple sclerosis (MS) were found to have greater cognitive problems, or difficulties thinking, than those without lesions in this area of mostly gray matter that surrounds the brain, a study reports.  Lesions confined to the…

Through two new initiatives, multiple sclerosis (MS) patients and their healthcare providers can contribute to a global effort to study and mitigate the impact of COVID-19 in MS and related disorders. The initiatives are aimed at helping clinicians identify the best way to manage the novel coronavirus in…

Vitamin D supplements promote a shift toward an anti-inflammatory state in people with multiple sclerosis (MS) through an increase of two key molecules, IL-27 and TGF-beta 1, a study shows. These findings add another level of regulation to a previous model linking the intake of vitamin…

Prescriptions of Roche’s Ocrevus (ocrelizumab) among multiple sclerosis (MS) patients initiating or switching a disease-modifying therapy (DMT) continue to rise in Europe, according to a survey conducted by Spherix Global Insights. Ocrevus, an anti-CD20 monoclonal antibody administered directly into a vein, was approved in the European Union to treat active forms…

A high genetic risk for multiple sclerosis (MS) is associated with structural alterations in white matter — brain regions composed mainly of nerve fibers — in childhood, findings from a large study show. Brain volume, however, was not affected by genetic risk in the more than 2,000 children whose…

Tysabri (natalizumab) is safe and shows robust, real-world effectiveness at reducing the frequency of relapses in people  with relapsing-remitting multiple sclerosis (RRMS), 10 years of data from a large, observational study report. Findings were reported in “Long-term safety and effectiveness of natalizumab treatment…

Treatment with Gilenya (fingolimod) could make people with multiple sclerosis (MS) more vulnerable to the parasitic infection known as cryptosporidiosis, a case report suggests. The report, “Cryptosporidiosis after treatment with fingolimod: a case report and pharmacovigilance review,” was published in the jorunal BMC Infectious Diseases. Gilenya…

A variant of the HLA-DRB1 gene — called HLA-DRB1*03 — appears to predispose people to developing multiple sclerosis (MS) in childhood, and to correlate with greater disease activity among those who do, a study in Greek patients suggests. The research also points to a protective role of one other variant of this…

Ursolic acid, a compound found in some herbs and in the peels of certain fruits, promoted nerve cell repair and restored the myelin sheath covering and protecting nerve endings in a mouse model of multiple sclerosis (MS), a study reported. Due to its strong anti-inflammatory and immunomodulatory…

The Consortium of Multiple Sclerosis Centers (CMSC) and the National Multiple Sclerosis Society have created a new database to track COVID-19 infections in people with multiple sclerosis (MS) and related diseases. The database, called COViMS (COVID-19 Infections in Multiple Sclerosis and Related Diseases),…

Changing the gut’s microbial community (microbiota) with antibiotics prevented the development of multiple sclerosis (MS), but not its progression after the disease was established, data from a mouse model of the disease show. These findings support evidence that microbiota manipulations affect inflammatory immune responses involved in MS development, but…

The small variants seen in the DNA code among individuals may affect the ability of oligodendrocytes to produce myelin, the protective coat surrounding neurons and whose destruction is a hallmark of multiple sclerosis (MS), a study reported. These findings open the possibility of new therapeutic options that target the…

Specialist inpatient rehabilitation is a cost-effective strategy that can improve the clinical outcomes of patients with multiple sclerosis (MS), particularly those at more advanced stages of the disease, a study in the United Kingdom (U.K.) found. The study, “Cost-efficiency of specialist inpatient rehabilitation for adults with…

In response to the COVID-19 pandemic, Atara Biotherapeutics has temporarily paused patient enrollment in the second and randomized part of its ongoing Phase 1 clinical trial investigating ATA188 in people with progressive forms of multiple sclerosis (MS). People treated in the first, open-label part of this trial, however,…

People exposed to secondhand cigarette smoke during adolescence may be more likely to develop multiple sclerosis (MS) later in life, a study suggests. The study, “Exposure to passive smoking during adolescence is associated with an increased risk of developing multiple sclerosis,” was published in the Multiple…

Plegridy (peginterferon beta-1a) and Avonex (interferon beta-1a), both by Biogen, may be used — if necessary — by women with relapsing multiple sclerosis who are pregnant or breastfeeding, the U.S. Food and Drug Administration (FDA) announced in updating prescribing information for these MS treatments. Due to the limited…

New or worsening headaches are a more common side effect of interferon-beta (IFN-beta) treatment in people with multiple sclerosis (MS) than previously appreciated, a new study suggests. The study, “Interferon-Beta-Induced Headache in Patients with Multiple Sclerosis: Frequency and Characterization,” was published in the Journal of Pain Research.

For multiple sclerosis (MS) patients with considerable disability, Ocrevus (ocrelizumab) appears to lower the risk of continued progression in both relapsing and primary progressive forms of the disease, data from an exploratory and post-hoc analysis of three Phase 3 trials report. These findings were in the study, “…

Physical exercise can ease fatigue in people with multiple sclerosis (MS) and potentially benefit them in many other ways, and should be part of rehabilitation programs for patients, a large review study suggests. The study, “The impact of physical exercise on the fatigue symptoms in patients with…

A study from Spain found the diet of multiple sclerosis (MS) patients to contain more fat and protein, and fewer carbohydrates, than recommended, which was linked to abdominal weight gain and higher levels of inflammation. As “an excessive intake of lipids” is known to be “related to oxidative stress…

Truxima, a biosimilar of rituximab, is comparable to the originator therapy in terms of effectiveness and safety for treating multiple sclerosis (MS), a new study suggests. Rituximab — marketed as Rituxan in the United States — is an antibody-based therapy that works by killing B-cells, which are immune cells…